Cohlhepp Ryan 4

What Happened
Ryan Cohlhepp, President, COO and Director of Bicara Therapeutics (BCAX), exercised 3,108 option shares (reported as an acquisition at $3.79 per share, total $11,779) and sold a total of 3,631 shares in open‑market transactions on Feb 25, 2026. The sales were reported at a weighted average price of $18.04 per share, generating aggregate proceeds of about $65,502. The filing indicates the trades were executed under an established Rule 10b5‑1 trading plan.

Key Details

• Transaction date: February 25, 2026; Form 4 filed February 27, 2026 (appears timely).
• Option exercise: 3,108 shares acquired at $3.79 each (total cost $11,779).
• Open‑market sales: 3,108 shares sold for ~$56,067 and 523 shares sold for ~$9,435; weighted average sale price $18.04 (sales ranged $18.00–$18.14 per F2).
• Additional derivative entry: a 3,108‑share derivative disposal reported at $0 (see footnotes/filing for mechanics).
• Shares owned after the transactions: not specified in the provided data.
• Footnotes: F1 — trades executed pursuant to a Rule 10b5‑1 plan adopted Feb 12, 2025; F2 — weighted average sale price with multiple execution prices; F3 — underlying options vest quarterly from Aug 8, 2023.

Context

• This was an exercise of options followed by immediate or same‑day sales of shares; that pattern often represents exercising to satisfy option cost/tax obligations or to monetize vested shares. The filing reports the exercise and sales on the same day and notes the 10b5‑1 plan, which sets predetermined trade instructions.
• The filing is factual and does not indicate the insider’s motivations. Purchases (acquisitions) can be more informative as a bullish signal; here the net cash received from sales ($65.5K) exceeds the cash paid to exercise ($11.8K).